Group 6D: HR+ Breast Cancer; Antibody-Drug Conjugates; Biomarkers; Clinical Trials

Poster #558: Association of tumor-infiltrating lymphocytes (TILs) and immune signatures with PAM50 intrinsic subtyping hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of two multicentric neoadjuvant trials.

Poster #1075: Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.

Date

Jun 13 2024

Time

6:00 pm - 7:30 pm

Zoom Webinar

Category
REGISTER